Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

692
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
692
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

430
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
430
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

1.5K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.5K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

4.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

564
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
564
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

504
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
504

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomic profiling of responses to clinical and novel bisphosphonates reveals extraskeletal effects on ageing related signatures.

Signal transduction and targeted therapy·2026
Same author

The role of supraoptic hypothalamic arginine vasopressin neurons in aging-associated water balance and thermoregulatory deficits in male mice.

Nature communications·2026
Same author

Distinct senescent β-cell senotypes differentially drive islet aging and dysfunction.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2.

Nature cancer·2026
Same author

The Downstream Effects of Prehospital Opioid Dosing in Older Adults: A Retrospective Cohort Study.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2026
Same author

Upskilling in Healthy Longevity Medicine and Its Association With Physicians' Implementation Intent and Self-Reported Clinical Confidence: Cross-Sectional Observational Study.

JMIR medical education·2026

Related Experiment Video

Updated: Nov 14, 2025

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.4K

Senolytics: Potential for Alleviating Diabetes and Its Complications.

Allyson K Palmer1, Tamar Tchkonia1, James L Kirkland1

  • 1Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota 55905, USA.

Endocrinology
|March 11, 2021
PubMed
Summary

Senolytic compounds selectively clear aging cells, offering a promising new approach to treat metabolic dysfunction, type 2 diabetes, and related complications. Clinical trials are needed to safely translate these findings into human therapies.

Keywords:
agingcellular senescencediabetes complicationsdiabetes mellitus

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.0K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

668

Related Experiment Videos

Last Updated: Nov 14, 2025

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.4K
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

5.0K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

668

Area of Science:

  • Gerontology
  • Metabolic diseases
  • Cellular biology

Background:

  • Cellular senescence, the accumulation of aging cells, is a key driver of metabolic dysfunction and type 2 diabetes.
  • Senescent cells contribute to the pathogenesis of diabetes and its complications.

Purpose of the Study:

  • To review the role of cellular senescence in type 2 diabetes and its complications.
  • To present evidence for senolytic therapy in preclinical models.
  • To outline senolytic drugs and clinical trial designs for diabetes.

Main Methods:

  • Literature review of cellular senescence in diabetes.
  • Analysis of preclinical data on senolytic interventions.
  • Examination of senolytic drug classes.
  • Discussion of clinical trial design for senolytic therapy in diabetes.

Main Results:

  • Targeting cellular senescence shows promise in preclinical models for improving metabolic function and reducing diabetes complications.
  • Senolytic drugs offer a potential therapeutic strategy for obesity and type 2 diabetes.
  • Intermittent administration of senolytics may improve adherence and reduce side effects.

Conclusions:

  • Cellular senescence is a fundamental aging mechanism implicated in metabolic dysfunction and diabetes.
  • Senolytic therapies represent a novel therapeutic class for treating obesity, diabetes, and their complications.
  • Well-designed clinical trials are essential for translating senolytic discoveries into human treatments.